Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke

Objective: To analyze the frequency, clinical characteristics, and predictors of symptomatic intracerebral hemorrhage (ICH) after intraarterial (IA) thrombolysis with recombinant pro-urokinase (r-proUK) in acute ischemic stroke. Method: The authors conducted an exploratory analysis of symptomatic ICH from a randomized, controlled clinical trial of IA thrombolysis with r-proUK for patients with angiographically documented occlusion of the middle cerebral artery within 6 hours from stroke onset. Patients (n = 180) were randomized in a ratio of 2:1 to either 9 mg IA r-proUK over 120 minutes plus IV fixed-dose heparin or IV fixed-dose heparin alone. As opposed to intention to treat, this analysis was based on “treatment received” and includes 110 patients given r-proUK and 64 who did not receive any thrombolytic agent. The remaining six patients received out-of-protocol urokinase and were excluded from analysis. The authors analyzed centrally adjudicated ICH with associated neurologic deterioration (increase in NIH Stroke Scale [NIHSS] score of ≥4 points) within 36 hours of treatment initiation. Results: Symptomatic ICH occurred in 12 of 110 patients (10.9%) treated with r-proUK and in two of 64 (3.1%) receiving heparin alone. ICH symptoms in r-proUK–treated patients occurred at a mean of 10.2 ± 7.4 hours after the start of treatment. Mortality after symptomatic ICH was 83% (10/12 patients). Only blood glucose was significantly associated with symptomatic ICH in r-proUK–treated patients based on univariate analyses of 24 variables: patients with baseline glucose >200 mg/dL experienced a 36% risk of symptomatic ICH compared with 9% for those with ≤200 mg/dL (p = 0.022; relative risk, 4.2; 95% CI, 1.04 to 11.7). Conclusions: Symptomatic ICH after IA thrombolysis with r-proUK for acute ischemic stroke occurs early after treatment and has high mortality. The risk of symptomatic ICH may be increased in patients with a blood glucose >200 mg/dL at stroke onset.

[1]  G. Albers,et al.  Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. , 2000, JAMA.

[2]  A. Furlan,et al.  Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. , 2000, JAMA.

[3]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[4]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[5]  T Moulin,et al.  Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. , 1999, Stroke.

[6]  D. Tanné,et al.  Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey , 1999, Neurology.

[7]  A. Demchuk,et al.  Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. , 1999, Stroke.

[8]  Wei Li,et al.  Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. , 1998, Stroke.

[9]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[10]  J. Lepercq,et al.  Diagnosis and Management of Intrauterine Growth Retardation , 1998, Hormone Research in Paediatrics.

[11]  R. Califf,et al.  Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1998, Stroke.

[12]  R. Higashida,et al.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. , 1998, Stroke.

[13]  J. Grotta,et al.  Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. , 1998, Stroke.

[14]  J. Grotta,et al.  Intravenous thrombolysis for acute stroke , 1997, Neurology.

[15]  G. Murray,et al.  Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study , 1997, BMJ.

[16]  V Larrue,et al.  Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. , 1997, Stroke.

[17]  N. Kawai,et al.  Hyperglycemia and the vascular effects of cerebral ischemia. , 1997, Acta neurochirurgica. Supplement.

[18]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[19]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[20]  D. Reich,et al.  Balo's concentric sclerosis: a rare form of multiple sclerosis manifested as a dominant cerebral mass without other white matter lesions on MR. , 1993, AJR. American journal of roentgenology.

[21]  S. Trittmacher,et al.  Hemorrhagic Transformation in Cardioembolic Cerebral Infarction , 1993, Stroke.

[22]  R. Busto,et al.  Moderate Hyperglycemia Worsens Acute Blood‐Brain Barrier Injury After Forebrain Ischemia in Rats , 1993, Stroke.

[23]  Marcello Pagano,et al.  Principles of Biostatistics , 1992 .

[24]  W. Hacke,et al.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke , 1992, Annals of neurology.

[25]  C. Kase,et al.  Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. , 1992, The American journal of medicine.

[26]  R. Myers,et al.  Hemorrhagic infarct conversion in experimental stroke. , 1992, Annals of emergency medicine.

[27]  H. Ishibashi-Ueda,et al.  Hemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke. , 1989, Stroke.

[28]  J. Bland.  Using and understanding medical statistics. (2nd edition) D. F. Matthews and V. T. Farewell, Karger, Basel, Switzerland, 1988. No. of pages: xii + 228. Price £18.20 ($26.75) , 1989 .

[29]  S. Rehncrona,et al.  Brain Lactic Acidosis and Ischemic Cell Damage: 2. Histopathology , 1981, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  R. D. Adams.  Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. , 1950, The Journal of clinical investigation.